Genovis Q2 2025: Undramatic report but recent developments are case supporting - Redeye
Redeye updates its view on Genovis' following a Q2 2025 report falling slightly short of our estimates and the recently expanded licese agreement with Thermo Fischer which we find supportive to the long-term case.
ANNONS
Redeye updates its view on Genovis' following a Q2 2025 report falling slightly short of our estimates and the recently expanded licese agreement with Thermo Fischer which we find supportive to the long-term case.
